296 related articles for article (PubMed ID: 18471786)
1. Androgen deprivation therapy for precancerous lesions of the prostate.
Hull D; Bostwick DG
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):285-91. PubMed ID: 18471786
[TBL] [Abstract][Full Text] [Related]
2. Morphological changes induced by androgen blockade in normal prostate and prostatic carcinoma.
Têtu B
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):271-83. PubMed ID: 18471785
[TBL] [Abstract][Full Text] [Related]
3. Intra-prostatic androgen levels during various androgen-blockade regimens.
Nishiyama T
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
[TBL] [Abstract][Full Text] [Related]
4. Intermediate biomarkers for chemoprevention of prostate cancer.
van der Kwast TH
IARC Sci Publ; 2001; 154():199-205. PubMed ID: 11220659
[TBL] [Abstract][Full Text] [Related]
5. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
Scherr DS; Pitts WR
J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
[TBL] [Abstract][Full Text] [Related]
6. Functional heterogeneity of prostatic intraepithelial neoplasia: the duration of hormonal therapy influences the response.
Kang TY; Nichols P; Skinner E; Groshen S; Valin G; Ye W; Raghavan D
BJU Int; 2007 May; 99(5):1024-7. PubMed ID: 17244277
[TBL] [Abstract][Full Text] [Related]
7. Prostatic intraepithelial neoplasia and prostate cancer.
Montironi R; Santinelli A; Mazzucchelli R
Panminerva Med; 2002 Sep; 44(3):213-20. PubMed ID: 12094135
[TBL] [Abstract][Full Text] [Related]
8. Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials.
Bostwick DG; Aquilina JW
J Cell Biochem Suppl; 1996; 25():156-64. PubMed ID: 9027613
[TBL] [Abstract][Full Text] [Related]
9. Histopathological effects of androgen deprivation in prostatic cancer.
Civantos F; Soloway MS; Pinto JE
Semin Urol Oncol; 1996 May; 14(2 Suppl 2):22-31. PubMed ID: 8725888
[TBL] [Abstract][Full Text] [Related]
10. Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia.
Bostwick DG; Qian J
Urology; 2001 Aug; 58(2 Suppl 1):91-3. PubMed ID: 11502458
[TBL] [Abstract][Full Text] [Related]
11. [Is tumour grade applicable to finasteride-treated prostate cancer?].
Molinié V; Ruffion A; Allory Y; Leroy X; Cochand Priollet B; Paraf F; de la Taille A
Prog Urol; 2005 Jun; 15(3):387-91. PubMed ID: 16097140
[TBL] [Abstract][Full Text] [Related]
12. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.
Iczkowski KA; Qiu J; Qian J; Somerville MC; Rittmaster RS; Andriole GL; Bostwick DG
Urology; 2005 Jan; 65(1):76-82. PubMed ID: 15667867
[TBL] [Abstract][Full Text] [Related]
13. Secondary hormonal therapy.
Smith DC
Semin Urol Oncol; 1997 Feb; 15(1):3-12. PubMed ID: 9050134
[TBL] [Abstract][Full Text] [Related]
14. The biological basis for the use of an anti-androgen and a 5-alpha-reductase inhibitor in the treatment of recurrent prostate cancer: Case report and review.
Wang LG; Mencher SK; McCarron JP; Ferrari AC
Oncol Rep; 2004 Jun; 11(6):1325-9. PubMed ID: 15138573
[TBL] [Abstract][Full Text] [Related]
15. Secondary hormonal therapy for advanced prostate cancer.
Lam JS; Leppert JT; Vemulapalli SN; Shvarts O; Belldegrun AS
J Urol; 2006 Jan; 175(1):27-34. PubMed ID: 16406864
[TBL] [Abstract][Full Text] [Related]
16. Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
Vis AN; Schröder FH
BJU Int; 2009 Nov; 104(9):1191-7. PubMed ID: 19624596
[TBL] [Abstract][Full Text] [Related]
17. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
[TBL] [Abstract][Full Text] [Related]
18. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
Rove KO; Crawford ED
Curr Opin Urol; 2013 May; 23(3):208-13. PubMed ID: 23492838
[TBL] [Abstract][Full Text] [Related]
19. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
20. Maximal androgen blockade for advanced prostate cancer.
Klotz L
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]